人胶质瘤干细胞样抗原致敏树突状细胞疫苗Ⅰ期临床试验研究

摘要

目的 探讨胶质瘤干细胞样抗原致敏DC疫苗在临床应用的可行性、安全性及有效性.方法 选取5例复发胶质瘤患者;二次手术后体外无血清培养胶质瘤细胞,CD133磁珠分选和X线照射后获取干细胞样抗原;同体外周血单核细胞经GM-CSF、IL-4诱导后再与干细胞样抗原共孵育获得成熟DC疫苗;每周1次皮下接种DC疫苗,共3次,联合替莫唑胺化疗.观察不良反应,头颅MRI增强随访及生存期评估疗效.结果 5例胶质瘤标本中均含有不同比率的CD133+细胞,DC疫苗接种后患者无明显不良反应,患者平均生存期为72.2周.结论 干细胞样抗原致敏DC疫苗对于胶质瘤患者安全可行,联合化疗能延长患者生存期.%Objective To investigate the feasibility ,safety and efficiency of dendritic cells (DCs) vaccine pulsed with tumor stem - like associated antigens against malignant glioma in recurrent patients.Method Cells derived from fresh specimens of recurrent gliomas in serum - free medium were magenetically sorted with CD133 -antibody and irradiated with X -ray to attain freeze -thaw lysates.Autologous DCs from mononuclear cells with GM-CSF and IL-4 were matured by the lysates.Five patients with recurrent glioma received the DCs vaccine once a week (3 times ) followed combination with chemotherapy after recurrent tumor resection.Follow - up was procedured with MRI scans and clinical protocol.Results Five malignant glioma cell lines contained different ratio of CD133 + cells.DCs were successfully prepared and applied in all patients.No side -effect was observed.Mean survival time was 72.2 weeks.Conclusions Combination of DCs vaccine and chemotherapy is safe and may benefit the patients with malignant glioma.